Innovating and invigorating the clinical trial infrastructure for glomerular diseases-Reference-Cited by-同舟云学术

Innovating and invigorating the clinical trial infrastructure for glomerular diseases

Published:2021-03 Issue:3 Volume:99 Page:519-523
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Barisoni Laura,Barratt Jonathan,Campbell Kirk,Eva Lauren,Gillespie Barbara S.,Gipson Debbie,Huber Tobias,Jardine Meg,Kamil Elaine,Kretzler Matthias,Lee Lauren,Levtchenk Elena,Mehr Ali Poyan,Nachman Patrick H.,Oh Jun,Saleem Moin,Shankland Stuart J.,Smith Kimberly,Smokler Irv,Smoyer William,Tarnoff Josh,Thompson Aliza,Trachtman Howard,Udani Suneel,Vivarelli Marina,Walker Patrick,West Melissa,Rovin Brad H.

Publisher

Elsevier BV

Subject

Nephrology

Reference7 articles.

1. The number, quality, and coverage of randomized controlled trials in nephrology;Strippoli;J Am Soc Nephrol,2004

2. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration;Levey;Am J Kidney Dis,2009

3. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration;Levey;Am J Kidney Dis,2014

4. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis;Troost;Clin J Am Soc Nephrol,2018

5. Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH;Coyne;Curr Prob Cancer,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome;Pediatric Nephrology;2022-08-15

2. Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders;Autoimmunity Reviews;2022-03

3. The Canadian Glomerulonephritis Registry (CGNR) and Translational Research Initiative: Rationale and Clinical Research Protocol;Canadian Journal of Kidney Health and Disease;2022-01

4. The PMDA’s view on the limited pipeline of nephrology drugs in Japan;Kidney International;2021-07